Recruiting

Trial ID CA246-0005 | NCT05737706

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Summary

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA.
Unresectable or metastatic disease.
Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts.
Presence of tumor lesions to be evaluated per RECIST v1.1: 1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease. 2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Age ≥ 18 years

Active brain metastases or carcinomatous meningitis.
Prior treatment with a KRAS G12D inhibitor (Phase 1b & Phase 2 only).
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications.
History of malignant small bowel obstruction.
Cardiac abnormalities.

Additional Information *

Study Arms

Experimental: Phase 1/1B

ASSIGNED INTERVENTION

Study Arms

Experimental: Phase 2

ASSIGNED INTERVENTION

Take the first step to see if you Match to a Clinical Trial – Check if you qualify

Check if you qualify

Answer some questions about Your health to see if you may match to this trial

Match to a Trial

If you are a match, click on the study to see the list of study site locations

Select a Study Site Location

Select a study site location that is convenient for you

Provide your contact details for the study site to connect with you.